KALA Stock Summary and Trading Ideas (Kala Bio | NASDAQ:KALA)

Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

Kala Bio trades on the NASDAQ stock market under the symbol KALA.

As of September 18, 2026, KALA stock price declined to $0.55 with 16,316 million shares trading.

KALA has a beta of 2.31, meaning it tends to be more sensitive to market movements. KALA has a correlation of 0.01 to the broad based SPY ETF.

KALA has a market cap of $10.64 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, KALA traded as high as $1,030.00 and as low as $.49.

The top ETF exchange traded funds that KALA belongs to (by Net Assets): VXF.

KALA has underperformed the market in the last year with a price return of -99.9% while the SPY ETF gained +16.3%. KALA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -80.7% and -2.0%, respectively, while the SPY returned +3.0% and -1.8%, respectively.

KALA support price is $.51 and resistance is $.62 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KALA shares will trade within this expected range on the day.